ARCT News and Press, Arcturus Therapeutics Ltd. From 05/07/24

2024-05-07 17:35:59 ET Major earnings expected after the bell on Wednesday include: Energy Transfer LP ( ET ) Airbnb ( ABNB ) The Trade Desk ( TTD ) AMC Entertainment Holdings ( AMC ) Innovative Industrial Properties ( IIPR ) Read the full a...

2024-05-07 17:19:14 ET More on Arcturus Therapeutics Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript As more rare disease therapies launch, their prices are...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will ...

2024-04-23 06:01:16 ET Summary Arcturus Therapeutics' ARCT-032 gene therapy for cystic fibrosis has been designated as an "orphan drug" in the U.S. and Europe. The therapy has the potential to generate significant revenues, similar to Vertex Pharmaceuticals' Trikafta treatment. ...

2024-04-16 12:22:50 ET More on rare disease pharmas/biotechs Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success...

2024-03-20 17:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-07 18:32:11 ET Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Conference Call March 07, 2024 04:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations & Marketing. Joe Payne - President &a...

2024-03-07 16:02:49 ET More on Arcturus Therapeutics Why Arcturus Therapeutics Has A Promising Future With Innovative CF And COVID Treatments Arcturus: H1 2024 Rare Disease Drug Data On Deck Arcturus Therapeutics Q4 2023 Earnings Preview Arcturus gets EU orph...

Kostaive® anticipated to launch in Japan this year ARCT-032 remains on track for Phase 1b interim data in Q2 ARCT-810 remains on track for Phase 2 interim data by the end of Q2 ARCT-2138 (Quadrivalent LUNAR-FLU) Phase 1 study for seasonal influenza vaccine initiated ...

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...